Vaxcyte, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vaxcyte, Inc. (PCVX) on February 24, 2026. The filing discloses the execution of a new sales agreement for the potential issuance of common stock and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
- New Offering Capacity: Entered into a Sales Agreement with Leerink Partners LLC to sell up to $500,000,000 of common stock.
- Compensation: The Placement Agent is entitled to a commission of up to 3.00% of gross proceeds from shares sold.
- Prior Agreement History: Terminated the previous Open Market Sale Agreement with Jefferies LLC. Under the prior agreement, the Company sold shares with an aggregate offering price of approximately $270.3 million.
- Financial Performance: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the replacement of the placement agent and the establishment of a new $500 million sales facility. The Company terminated its previous agreement with Jefferies LLC effective February 24, 2026, and simultaneously engaged Leerink Partners LLC under a new agreement. Sales under the new agreement may be conducted as "at the market" offerings on the Nasdaq Global Select Market or through other permitted methods.
Outlook, Risks, and Contingencies
- Discretionary Nature: The Company is not obligated to sell any shares, and the Placement Agent is not obligated to buy or sell any shares.
- Uncertainty: No assurance is given regarding whether shares will be sold, the price at which they may be sold, the number of shares sold, or the timing of such sales.
- Legal Framework: The shares are registered under an effective shelf registration statement on Form S-3 (File No. 333-279735).
Key Facts for Investor Verification
- Verify the current market price of PCVX to assess potential dilution if the full $500 million is sold.
- Review the Company's most recent 10-K or 10-Q for actual cash position and burn rate to determine the necessity of this capital raise.
- Confirm the specific terms of the 3.00% commission fee and any other transaction costs in the attached Sales Agreement (Exhibit 1.1).
- Monitor future filings for actual sales activity under the new agreement, as no sales are guaranteed.